More Community Vaccine Clinics in February

The Grey-Bruce Health Unit has announced the addition of new community COVID-19 vaccine clinics in February. Clinics are in Grey-Bruce communities with the lowest vaccine coverage rate. This concentrated effort will enable Public Health to serve those with the lowest vaccination rates, increasing COVID-19 protection in populations with the lowest vaccine coverage rate.

In addition, two child-based clinics for children aged 5 to 11 are planned for February 5 and 6. For more information, please see the schedule. Only children aged 5 to 11 will be able to receive the vaccine at these two clinics. All eligible individuals are welcomed at all other clinics.

It is recommended that you book your appointment to prevent wait-times; however, walk-ins are welcome at all clinics. To book you appointment, please call or book online at:

· Provincial Vaccine Contact Centre at 1-833-943-3900

· How to book a COVID-19 vaccine appointment (ontario.ca) (https://covid-19.ontario.ca/book-vaccine/)

Those 5-11 are eligible for their first and second dose. It is strongly recommended that second doses for this age group be given at least eight weeks after the first dose. For those aged 5-11, the COVID-19 vaccines should be booked at least 14 days before or after other vaccines. Second dose appointments ARE NOT automatically booked when booking your first dose.

Those 12-18, are eligible for first and second dose at these clinics.

Individuals 18 and over are eligible to receive their first, second and booster dose at these clinics.

Some individuals who are immunocompromised can get:

a third dose of the COVID-19 vaccine eight weeks after their second dose as part of an extended primary series
a fourth dose (booster) three months (84 days) after completion of the three-dose primary series

Contact your health care provider to see if you are eligible for the third or fourth dose referenced above

You might be eligible if you are:

a transplant recipient (including solid organ transplant and hematopoietic stem cell transplants)
receiving stable, active treatment (chemotherapy, targeted therapies, immunotherapy) for a malignant hematologic disorder or solid tumor
in receipt of chimeric antigen receptor (CAR)-T-cell
an individual with moderate or severe primary immunodeficiency (for example, DiGeorge syndrome, Wiskott-Aldrich syndrome)
Stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome
undergoing active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive or are taking specific immunosuppressant medications (PDF)
receiving dialysis (hemodialysis or peritoneal dialysis)